Product Revenues ** Change in excess of 100% 35 Year Ended December 31, % Change Dollars in Millions 2018 2017 2016 2018 vs. 2017 2017 vs. 2016 Prioritized Brands Opdivo $ 6,735 $ 4,948 $ 3,774 36 % 31 % U.S. 4,239 3,102 2,664 37  % 16  % Non-U.S. 2,496 1,846 1,110 35 % 66 % Eliquis 6,438 4,872 3,343 32 % 46 % U.S. 3,760 2,887 1,963 30  % 47  % Non-U.S. 2,678 1,985 1,380 35 % 44 % Orencia 2,710 2,479 2,265 9 % 9 % U.S. 1,875 1,704 1,532 10  % 11  % Non-U.S. 835 775 733 8 % 6 % Sprycel 2,000 2,005 1,824 — 10 % U.S. 1,091 1,105 969 (1 )% 14  % Non-U.S. 909 900 855 1 % 5 % Yervoy 1,330 1,244 1,053 7 % 18 % U.S. 941 908 802 4  % 13  % Non-U.S. 389 336 251 16 % 34 % Empliciti 247 231 150 7 % 54 % U.S. 164 151 133 9  % 14  % Non-U.S. 83 80 17 4 % ** Established Brands Baraclude 744 1,052 1,192 (29 )% (12 )% U.S. 32 53 66 (40)% (20)% Non-U.S. 712 999 1,126 (29 )% (11 )% Reyataz Franchise 427 698 912 (39 )% (23 )% U.S. 157 327 484 (52)% (32)% Non-U.S. 270 371 428 (27 )% (13 )% Sustiva Franchise 283 729 1,065 (61 )% (32 )% U.S. 27 622 901 (96)% (31)% Non-U.S. 256 107 164 ** (35 )% Hepatitis C Franchise 17 406 1,578 (96 )% (74 )% U.S. (16) 109 827 ** (87)% Non-U.S. 33 297 751 (89 )% (60 )% Other Brands 1,630 2,112 2,271 (23 )% (7 )% U.S. 316 390 379 (19)% 3 % Non-U.S. 1,314 1,722 1,892 (24 )% (9 )% Total Revenues 22,561 20,776 19,427 9  % 7  % U.S. 12,586 11,358 10,720 11 % 6 % Non-U.S. 9,975 9,418 8,707 6  % 8  %